Current Advances and Challenges in Pharmaceutical Formulation Development and Manufacturing: A Comprehensive Review for Industry Applications

Pharmaceutical formulation development and manufacturing have evolved rapidly with the advent of nanotechnology-enabled delivery, biopharmaceuticals, continuous manufacturing, and data-driven quality systems. This review synthesizes the state-of-the-art across formulation science and production technologies, with emphasis on industry adoption, regulatory expectations, and practical barriers. We discuss nano- and micro-structured drug products, patient-centric and long-acting designs such as implantable depots and microneedle patches, lyophilization and stabilization of biologics including monoclonal antibodies and vaccines, and digital design-of-experiments under Quality-by-Design (QbD). On the manufacturing side, we examine continuous processing for solid oral dosage forms, Process Analytical Technology (PAT) integrated with real-time monitoring, automation and robotics in aseptic filling lines, and technology transfer from lab to commercial scale. Persistent challenges include material variability from natural excipients, scale-up/scale-out complexities in multiphase systems, regulatory compliance amid evolving FDA/EMA guidelines, cost-to-value trade-offs in personalized medicine, and sustainability concerns like waste generation in solvent-based processes. Critically, we highlight how these challenges can lead to delays in tech-transfer or increased failure rates, as evidenced by recent industry reports from companies like Pfizer and Novartis. In addition to summarizing scientific advances, this review aims to provide practical insights for researchers and industry stakeholders by mapping opportunities against known limitations and regulatory expectations. The inclusion of recent case studies, such as lipid nanoparticle scaling for mRNA vaccines, and decision frameworks is intended to support both academic and industrial audiences. Actionable recommendations and future directions—AI-augmented development for predictive modeling, model-informed control strategies, and green chemistry principles—are proposed to accelerate reliable, affordable, and resilient supply, drawing from 2024–2025 trends in Pharma 4.0.